Clinical Activity and Safety Profile of TGR-1202, a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity in Patients with CLL and B-Cell Lymphoma.

Drug Category: Array
Conference Category: Array
Lead Author: O'Connor, et al.
Published Date: 20/06/2015
Download Link: /wp-content/uploads/2019/03/O'ConnorTGR202Single%20AgentEHA&Lugano2015(1).pdf
Download Text: Download
Popup Confirmation?:
site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
astra-migrate-meta-layouts: set
Scroll to Top